Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs DBVT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: LCTX 3 – 2 DBVT (1 Tie) Matrix Metrics: LCTX 6 – 3 DBVT

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas DBVT carries 43.0/100 (HOLD) at $9.42 (N/M Forward P/E, -5577.0% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. DBVT 43.0/100 HOLD) and 1.36β · 79% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile DBVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs DBVT
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$9.42
-2.69% 1D
Market Cap $619.6M
TTM Revenue $3.7M
Forward P/E N/M
Beta / 30D Vol 1.19β · 75% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.3%), weak momentum, RSI 42
RSI-14: 41.6 · SMA20: $10.30 · SMA50: $10.57

6-Pillar Scorecard Institutional Category Breakdown (LCTX 3 – 2 DBVT)

Columns: Metric · LCTX · DBVT
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 16.3x 123.5x
2. Growth & Scale DBVT
Revenue Growth (YoY) -61.0% -42.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $3.7M
Market Cap $212.1M $619.6M
3. Profitability & Quality LCTX
Gross Margin -95.0% 100.0%
Operating Margin -280.3% -5577.0%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -205.8%
4. Balance Sheet & Cash Flow DBVT
Cash Generation (TTM) -$24M -$192M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $158M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LCTX
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 896.2% (100th %ile) 64.5% (13th %ile)
Put/Call OI Skew 1.10x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (6) vs DBVT (3)
Institutional Metric LCTX DBVT Criterion Row Edge
Market Capitalization
Scale
$212.1M $619.6M Larger Scale DBVT
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% -42.9% Higher Growth DBVT
Operating Margin (TTM)
Profitability
-280.3% -5577.0% Higher Margin LCTX
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -205.8% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 4% ($9–$26) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 1.19β · 75% Vol Lower Realized Risk DBVT
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 43.0 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $3.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · 123.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$192M ($158M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DBVT +11.74 pp
LCTX: -13.82% · DBVT: -2.08%
3M Horizon LCTX +11.19 pp
LCTX: -24.07% · DBVT: -35.26%
6M Horizon LCTX +11.39 pp
LCTX: -37.88% · DBVT: -49.27%
1Y Horizon DBVT +21.29 pp
LCTX: -53.67% · DBVT: -32.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue DBVT Revenue LCTX Op. Margin DBVT Op. Margin Margin Leader
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M $10M -1106.0% -1162.8% LCTX
FY2020 $0M $10M -1448.4% -1408.7% DBVT
FY2021 $0M $10M -1133.6% -1727.6% LCTX
FY2022 $10M $0M -153.2% -1994.9% LCTX
FY2023 $10M $20M -276.5% -486.0% LCTX
FY2024 $10M $0M -226.1% -2808.7% LCTX
FY2025 $10M $10M -251.6% -2609.2% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DBVT SURGE
6d in phase · OBV DISTRIBUTION
Current IV 64.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DBVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $619.6M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs DBVT Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas DBVT carries 43.0/100 (HOLD) at $9.42 (N/M Forward P/E, -5577.0% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. DBVT 43.0/100 HOLD) and 1.36β · 79% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile DBVT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DBVT leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with DBVT at -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while DBVT shifted +0.0%. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DBVT.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 123.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus DBVT (-205.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.19β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.